liver-specific glucokinase activators (Ligand Pharmaceuticals)

N/A

Report date: 2025/03/20 15:36:14
NME

Base Information

Drug Nameliver-specific glucokinase activators (Ligand Pharmaceuticals)
Drug Alias Nameglucokinase activators (Ligand Pharmaceuticals)glucokinase activators (Metabasis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucokinase activators
TargetsGlucokinase
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMetabasis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesLigand Pharmaceuticals Inc
Inactive CompaniesMetabasis Therapeutics Inc
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A